Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- MSD Urges Expansion of Exclusion Criteria for Spillover Rules as Repeated Cuts Hit Keytruda
July 28, 2021
- Meiji to Sell JV Stake to Dong-A, but Will Continue Biosimilar Collaboration
July 28, 2021
- Takeda, PeptiDream Expand Collaboration into Neurodegenerative Disease Area
July 28, 2021
- Daiichi Sankyo Espha, Meiji Pharma Launch Cymbalta Generics
July 28, 2021
- AnGes Adds High-Dose Trial to COVID-19 Vaccine Program
July 27, 2021
- Chugai’s H1 Sales Rise on Growth of Tecentriq, Kadcyla
July 27, 2021
- Shionogi’s Oral COVID-19 Drug Enters PI in Japan
July 27, 2021
- Moderna Vaccine’s Minimum Age Lowered to 12 in Japan
July 27, 2021
- Lenvima/Keytruda Gets Full US Approval for Endometrial Carcinoma
July 27, 2021
- Meiji Pharma Licenses Stelara Biosimilar to India’s Intas
July 26, 2021
- Rohto Begins Japan PIII for Topical Ganciclovir in CMV Corneal Endotheliitis
July 21, 2021
- Relugolix Combination Drug Approved in EU for Uterine Fibroids
July 21, 2021
- Kyowa Suspending Alfacalcidol Supply; Chugai Curbs Further Products
July 21, 2021
- Sanofi to Transfer Plaquenil’s Japan Marketing Rights to Asahi Kasei on Oct. 1
July 20, 2021
- Ono Initiates PII Trial of BTK Inhibitor Velexbru for PCNSL in US
July 20, 2021
- Shionogi Bags Rights to COVID-19 Nasal Vaccines
July 20, 2021
- Kyosomirai Controls Shipments for Generic Calcitriol Amid Vitamin D3 Preparation Shortage
July 20, 2021
- Shipment Adjustments/Pauses for Choseido-Made Products Grow to 42
July 20, 2021
- Sawai’s Shipment Restrictions Now Reaches 385 Products
July 20, 2021
- Towa to Launch Cymbalta Generics on Aug. 30, Nipro on July 21/27
July 19, 2021
ページ
The number of newly listed generic drugs in Japan has fallen sharply over the past decade, reflecting structural changes in…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…